Latest Priority Review Voucher Stories
WASHINGTON, Nov. 20, 2014 /PRNewswire/ -- Kids v Cancer is pleased to announce that a second priority review voucher was just sold by Knights Therapeutics to Gilead for $125 million.
Now that Childhood Rare Disease Drugs are Profitable, They Might Get Them WASHINGTON, Sept.
TARRYTOWN, N.Y. and PARIS, July 30, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
VioQuest Pharmaceuticals (OTCBB: VOQP) today announced that the United States Patent and Trademark Office has issued the first patent for the company's investigational product candidate Lenocta(TM) (sodium stibogluconate). U.S. Patent No.
By Maggie Fox, Health and Science Correspondent WASHINGTON (Reuters) - Companies that develop drugs to treat diseases of poor countries such as malaria should be rewarded with vouchers that might speed up government review of far more lucrative drugs, researchers proposed on Tuesday.
- totally perplexed and mixed up.